Ocrevus (ocrelizumab) and Tysabri (natalizumab) appear equally effective at controlling relapses and MS progression, a study ...
An existing drug currently used to treat glaucoma, altitude sickness, and seizures may also have the potential to prevent ...
Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.
A publicly available AI tool correctly predicted approximately twice as many children with acute lymphoblastic leukemia who ...
For decades, prevailing wisdom held that to overcome addiction, the most important thing to do was to flush or “clean” the drugs out of one’s system, to get a fresh start. But more and more, research ...
CareDx (NASDAQ:CDNA) used an investor webcast to outline its “Transplant Plus” expansion into cell therapy and to highlight ...
Relapse rates over 3 years did not differ with glucocorticoid withdrawal vs maintenance among patients with stable SjD-ILD.
Objectives Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease where infections ...
Despite great progress in curing childhood acute lymphoblastic leukemia (ALL), survival after relapse remains poor. We analyzed survival after relapse among 9585 pediatric patients enrolled on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results